20/01/2026
Voice Biota Awarded 2026 Global Recognition Award for Excellence in Voice Biomarker Innovation
Voice Biota has received a 2026 Global Recognition Award for exceptional achievement in advancing voice biomarker science into a practical, scalable system operating across consumer, enterprise, and clinical settings.
The Global Recognition Awards are highly competitive, with more than 15,000 applicants evaluated annually and only 5.8% receiving recognition, placing Voice Biota among a select group of organisations meeting international standards of excellence.
The independent judging panel recognised Voice Biota for translating rigorous scientific research into real-world deployment while maintaining medical-grade discipline in validation, data integrity, and system architecture. The award reflects Voice Biota’s work in addressing respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma through non-invasive voice and breathing analysis.
With over 1.5 million real-world voice-derived data points and a portfolio of 51 continuously validated voice-based biomarkers, Voice Biota has established one of the most extensive operational datasets in the field. Its live validation framework ensures sustained performance under real-world conditions, strengthening confidence among clinicians, regulators, and enterprise partners.
Judges also highlighted Voice Biota’s full-stack ecosystem, which connects population-level analytics, enterprise health insights, and clinically oriented respiratory monitoring through a unified architecture. This approach enables scalable deployment while preserving clear separation between wellness applications and regulated medical use.
Evaluation was conducted by impartial industry experts using a Rasch-based measurement model, ensuring objective comparison across disciplines. Voice Biota achieved top-tier scores for research originality, interdisciplinary collaboration, innovation, real-world applicability, and market readiness.
This recognition affirms Voice Biota’s position at the intersection of non-invasive digital biomarkers and rigorous medical validation, marking its progression from research innovation to measurable, global impact.